Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Former FDA commissioner joins J&J board

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva halts Israeli layoff plans amid pressure from labor, government

Teva Pharmaceutical Industries will back off its layoff plans in Israel--at least for now. Thanks to vociferous and colorful opposition from labor, plus worker support from politicians, Teva now pledges to negotiate with unions before cutting jobs.

Irate Teva reps vow to strike against Israeli job cuts

The job-cutting news out of Teva Pharmaceutical Industries has spawned some protest--on both sides of the issue. Israeli unions promise to strike if layoffs hit home--and, as if to pre-empt that talk, one Teva executive claims the cuts aren't nearly so bad as the media suggests.

Novartis whacks vaccine jobs as it eyes unit for disposal

The report this week that Novartis'  vaccine and diagnostic operation is one the company's  execs might want to unload  will not surprise employees at its Emeryville, CA, operation, where four dozen workers on the vaccine side have been given layoff notices.

Neuraltus names Richard Casey president, CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva plots 5,000 more job cuts in $2B savings drive

Teva Pharmaceutical Industries is already in the middle of a big cost-cutting push. And it's about to get bigger. The Israel-based generics giant plans to lay off up to 5,000 people, or about 10% of its work force, in a bid to squeeze $2 billion out of annual costs by 2017.

PhIII antibiotic developer gets a new name, new CEO in makeover

The New Haven, CT-based biotech Rib-X is undergoing a makeover. The biotech has a new name and is now being run by a new management team drawn in by a new lead investor. But it's still focused on the same lead antibiotic: delafloxacin.

Delcath axes one-third of staff after FDA rejection

Delcath's year of disappointment lumbers on as the New York company axes 21 of its 60 employees, looking to cut costs as it figures out just what to do with an FDA-rejected device.

Daiichi Sankyo shakes up U.S. leadership

The company said today that Glenn Gormley has been named corporate president and chairman of Daiichi Sankyo Inc. He takes over the president role from John Gargiulo, who's out as of yesterday. The company did not give a reason for the departure of Gargiulo, who had been president, CEO and head of Daiichi's commercial division.

Bill Weldon gets new chairman title at Chase Bank

William Weldon, who last year stepped down at Johnson & Johnson after running the company for years, has again added the title of chairman to his resume. In what The Wall Street Journal characterized as a stealth move, Weldon has replaced James Dimon in that role. Weldon was already a top director on the Chase board.